Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous iron regimen and cardiovascular complications in hemodialysis patients
IRCT20201108049311N1Phase 3Completed
- Sponsor
- Personal expense
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Iron in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by Personal expense. Primary endpoints: Decrease in required weekly dose of erythropoietin and Reduction in cardiovascular events. Started Sep 2020; status: completed.
02
Drugs
Iron
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20201108049311N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201108049311N1.